Erbse, Just wondering if you were able to copy/save the SHM slides? I usually copy them onto word documents, but for some reason these won't copy. Thanks.
Well, re-listening to the SHM webcast, as Neuro had already mentioned, there is no Cortex use patent covering ADHD (due to prior art), so it looks like Schering or anyone else can just go ahead with an AMPA upmodulator for ADHD without any license from Cortex. However, since Org-26576 was originally in-licensed from Cortex for Schizo/Depression, I assume they'll have to eventually update/modify that deal if they want to someday commercialize Org-26576 for ADHD. More importantly, if they're serious about ADHD, Schering will want control of a newer more potent Cortex low impact with the longer patent life. Varney showed a slide of animal data for CX-1739 which showed impressive ADHD activity, plus it has 3-10 times the potency of CX-717, and patent protection out to 2027.
Looking at the RD-2 slide, at the bottom of the slide they note that in addition to RD, the trial is to evaluate the safety of CX-717 when combined with alfenanil. So having an ultra high 2100 mg dose would provide additional combo safety data, so I suppose the need for that dose wouldn't necessarily only be because 1500 mg wasn't cutting it efficacy-wise.
Interestingly, the RD animal data for one of the new high impacts showed it to increase respiration way beyond baseline (approx twice the baseline rate). Amazing, and at only a miniscule dose of .05 mg/kg.
Market Data 
Markets 
AI
